It becomes more likely as diabetes lasts longer, glucose control remains poor, and other risk factorssuch as hypertension and kidney diseaseaccumulate
Your healthcare provider will tailor the dosage and frequency of semaglutide GLP-1 based on your individual needs, health profile, and progress
Monitoring: Cardiovascular: Heart rate (at regular intervals during Wegovy therapy) Gastrointestinal: For signs/symptoms of acute pancreatitis (after starting this drug) Metabolic: Blood glucose in patients with diabetes mellitus (before starting and during Wegovy therapy) Ocular: For progression of diabetic retinopathy in patients with history of diabetic retinopathy Renal: Renal function in patients with adverse reactions that could lead to volume depletion (during therapy, especially during initiation and escalation) Patient advice: Read the US FDA-approved patient labeling (Medication Guide and Instructions for Use, as applicable)
Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A (2019) Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity